Latest Rofecoxib Stories
A new study published in the British Medical Journal (BMJ) on Wednesday warns that taking specific types of pain relievers could increase a person's risk of suffering a stroke or other heart-related ailment.
Nonmelanoma skin cancers are some of the most commonly diagnosed in the US A new study found a possible preventative treatment in the nonsteroidal, anti-inflammatory drug Celecoxib.
A research team from the University of California, Davis and Peking University, China, has discovered a novel mechanism as to why the long-term, high-dosage use of the well-known arthritis pain medication, Vioxx, led to heart attacks and strokes.
Common painkillers have been linked to risks of heart attack may also increase the risk of stroke.
A panel of US Food and Drug Administration advisers voted Wednesday to allow GlaxoSmithKline's diabetes drug Avandia to remain on the market, but with new restrictions due to the risky cardiovascular side effects of the controversial pill.
LOS ANGELES, April 10 /PRNewswire/ -- In selecting U.S. District Judge James V. Selna to hear more than 100 federal lawsuits filed around the country against Toyota, a federal judicial panel also granted a formal request by the Lanier Law Firm to rename the litigation and expand its scope.
HOUSTON, March 3 /PRNewswire/ -- The Lanier Law Firm is announcing a lawsuit filed today in Harris County state district court by the family of a Houston woman who was injured in a crash while driving a Toyota Camry with a defective acceleration control system. Attorney Mark Lanier, founder of The Lanier Law Firm, and Tammy Tran of Houston's The Tammy Tran Law Firm are representing Anna Pham and her mother Natalie Pham in their claims against Toyota Motor Corp.
MONTGOMERY, Ala., Feb. 23 /PRNewswire/ -- Beasley Allen attorney Graham Esdale is in Washington, DC this week with three adult children of the firm's deceased client Barbara Schwarz. Esdale and clients, Margie Louise Meibergen, Sharon L.
The Food and Drug Administration fell short with drug approvals in 2009 and drug warnings were lacking, even as the FDAâ€™s new leadership adopted a tougher attitude on safety.
NEW YORK, Dec.